Clinical and Psychosocial Correlates of Post-Herpetic Neuralgia

A. Volpi,1* A. Gatti,2 F. Pica,3 S. Bellino,4 L.T. Marsella,1 and A.F. Sabato2
1Department of Public Health, University of Rome “Tor Vergata”, Rome, Italy
2Department of Surgery, University of Rome “Tor Vergata”, Rome, Italy
3Department of Experimental Medicine, University of Rome “Tor Vergata”, Rome, Italy
4Istituto Superiore di Sanità, Rome, Italy

INTRODUCTION

Herpes zoster results from the reactivation of latent Varicella zoster virus from the dorsal root and some cranial nerve ganglia. Although herpes zoster is not a reportable disease, 200,000–250,000 cases are estimated to occur annually in Italy [Di Luzio Paparatti et al., 1999]. Appropriate treatment controls acute herpes zoster symptoms and reduces the risk of longer term complications [Johnson and Dworkin, 2003]. Chronic pain also termed post-herpetic neuralgia is the most common complication of herpes zoster in immunocompetent hosts. It is characterized by constant or intermittent burning, itching or aching, with paroxysmal or lancinating pain. Other primary characteristics, such as numbness, tingling and allodynia, also contribute to the burden of post-herpetic neuralgia. Secondary characteristics of post-herpetic neuralgia include sleep disturbance, anorexia and weight loss, chronic fatigue and depression accompanied by social isolation. Post-herpetic neuralgia is also known as the debilitating, chronic pain that persists, in some individuals, for weeks, months or even years after the herpes zoster rash has healed. It causes suffering for the patient and a burden of economic cost on patient, care-givers and healthcare providers. Public awareness of the disease is poor, which may lead to delayed presentation for medical care at an early stage of the disease when antiviral drugs may be most beneficial. Despite advances in antiviral therapy during acute herpes zoster and the more recent introduction of vaccination against Varicella zoster virus [Oxman et al., 2005], post-herpetic neuralgia continues to be a significant clinical problem worldwide, with up to 10–25% of patients experiencing...
Correlates of Post-Herpetic Neuralgia


this condition [Cunningham and Dworkin, 2000]. Prevalence estimates of post-herpetic neuralgia, however, vary widely depending on the definition of post-herpetic neuralgia used, the population being studied and the adequacy of data [Coplan et al., 2004; Katz et al., 2004]. Although the definitions used in studies of post-herpetic neuralgia have been arbitrary and often inconsistent in the literature, it has recently been proposed that post-herpetic neuralgia exists when significant pain or dysesthesia persists for 3 or more months after rash healing [Dworkin and Portenoy, 1996]. The effects of post-herpetic neuralgia on physical and emotional functioning have been examined in several studies [Schmader et al., 1990; Dworkin et al., 1992; Dworkin and Portenoy, 1996; Whitley et al., 1999; Dworkin and Shmader, 2001; Nagasako et al., 2002; Thyregod et al., 2004]. Because the effect of treatment is disappointing once the syndrome has developed, it is important to know which factors predict post-herpetic neuralgia occurrence to facilitate selection of herpes zoster patients with a higher risk of developing post-herpetic neuralgia and undertake preventative strategies. Previous research identified several predictors of post-herpetic neuralgia [Higa et al., 1988; Dworkin et al., 1992; Dworkin and Portenoy, 1996; Choo et al., 1997; Whitley et al., 1998; Opstelten et al., 2002, 2007; Scott et al., 2003; Jung et al., 2004; Coen et al., 2006] but the prognostic value of combinations of physical and psychosocial predictors, based on multivariable prediction modeling, has not yet been assessed.

The aim of the present study is to analyze the relationship between baseline and 6-month follow-up data from 219 Italian immunocompetent herpes zoster patients to identify demographic, clinical and psychosocial correlates of post-herpetic neuralgia in relation to acute herpes zoster presentation.

MATERIALS AND METHODS

Patients

Five hundred thirty-three patients with a clinical diagnosis of herpes zoster, recruited by dermatologists in private practices nationwide from April to October 2001 on acute herpes zoster presentation, were asked to participate in a study of herpes zoster [Volpi et al., 2007], to complete a questionnaire and to return for a 6-month follow-up visit. Informed consent was obtained from all the patients who accepted. The dermatologists also collected medical and demographic data and provided counseling and therapy where appropriate. Two hundred nineteen patients returned at the follow-up visit.

Data Collection

The data examined in the present analyses were collected at the baseline visit, which occurred at the time of clinical diagnosis and enrolment, and at a follow-up visit 6 months later. In particular, the following data were analyzed: age, sex, pain intensity, the presence of a prodrome (defined as pain before rash onset) and its duration (range 1–more than 3 days), the extent of rash (rash involving 1, 2, or more than two dermatomes) and its localization, the presence of abnormal sensations (including itch, tingle and allodynia) and the use of systemic antiviral therapy.

At the baseline as well as at the follow-up visit, the physician collected the following information from the patients: demographic data, medical history, history of present disease, distribution of manifestations, clinical expression of disease and treatments. On both occasions, patients were also asked to complete the Short Italian Questionnaire, designed to evaluate the intensity of pain, psychological profile and quality of life [Serafini et al., 2003; Volpi et al., 2007]. It elicits information to reflect the level of anxiety or depression and the perceptions that an individual has about their pain and quality of life (worst pain over last week, physical and social functioning, vitality, physical and emotional role, psychological distress and well-being). Each item was scored between 0 (negative) and 10 (maximum).

In the present study patients presenting with pain rated as “3” or more on a scale ranging from 0 (“no pain”) to 10 (“pain as bad as you can imagine”) in the last week before the follow-up visit were considered as affected by post-herpetic neuralgia.

Statistical Analysis

Statistical analyses and data processing were performed using SAS software, version 8.2 for Windows™. All two-sided statistical tests were performed using a 5% significance level.

Quantitative variables were analyzed by descriptive statistics including mean values, standard deviation, median, minimum and maximum. Clinical and demographic characteristics were analyzed as categorical variables, whereas intensity of pain, anxiety, depression and quality of life were analyzed as continuous variables. The chi-square test for combined data was used to investigate the relationships between the demographic and clinical characteristics of patients with and without post-herpetic neuralgia. Pearson’s correlation coefficient was used to investigate differences in the psychosocial variables of patients at the baseline and at the follow-up visit. Logistic regression analysis was performed to analyze the relationship between post-herpetic neuralgia and the variables were significantly associated with post-herpetic neuralgia in the univariate analysis, that is, age, pain intensity, extent of rash, duration of prodromal pain, abnormal sensations and antiviral therapy.

RESULTS

Two hundred nineteen subjects enrolled in a study on acute herpes zoster presentation returned to the physician office for a follow-up visit 6 months later. They were all Caucasian Italians and were evenly distributed from various areas of the Country (data not shown). The
median age was 58 years (range 18–82) and 68% of them were over 50 years of age. There were more females than males (63% vs. 37%). Forty-eight percent of participants in the study had a high school education or university degree.

At the 6-month follow-up visit, 70 patients (32%) presented with post-herpetic neuralgia: among them, there were more females than males (60% vs. 40%), similarly to what happened in patients without post-herpetic neuralgia, and more people over 60 years of age than in the group of patients without post-herpetic neuralgia (64% vs. 38%, respectively; \( P < 0.0009 \)).

Demographic and clinical characteristics of the patients with and without post-herpetic neuralgia when first seen with herpes zoster (at baseline visit) are summarized in Table I.

Patients with and without post-herpetic neuralgia did not differ in relation to the presence of prodromal pain and in the overall localization of rash during acute herpes zoster (Table I). However, the ophthalmic localization resulted to be more frequent than the non-ophthalmic localization in patients presenting with post-herpetic neuralgia than in those without post-herpetic neuralgia (21% vs. 10%, respectively; \( P = 0.03; \) RR 1.77 (95% CI 1.12–2.8)).

Patients with and without post-herpetic neuralgia presented differences in relation to the duration of prodromal pain before rash (which was more than 3 days in 75% of patients with post-herpetic neuralgia vs. 24% of individuals without post-herpetic neuralgia), the extent of rash (which interested more than one dermatome in 43% of patients with post-herpetic neuralgia vs. 27% in those without post-herpetic neuralgia) and the intensity of pain at the baseline visit (mean score of pain intensity: 7.0 in patients with post-herpetic neuralgia vs. 5.5 in patients without post-herpetic neuralgia; \( P < 0.0155 \)). The presence of abnormal sensations on acute herpes zoster presentation was detected in 47% of patients who subsequently developed post-herpetic neuralgia versus 34% of those who did not (\( P = 0.047; \) RR 1.5 (95% CI: 1.02–2.22)). At the follow-up visit, 31% of patients with post-herpetic neuralgia referred the persistence of abnormal sensations.

Acyclovir, Valaciclovir or Famciclovir had been prescribed according to the guidelines [Volpi et al., 2005], within 72 hr from rash onset, in 79% of patients who developed post-herpetic neuralgia and in 97% of patients without post-herpetic neuralgia (\( P < 0.001 \)).

The psychosocial characteristics of patients with and without post-herpetic neuralgia, when first seen during acute herpes zoster and 6 months later, are shown in Table II. At the follow-up visit, patients with post-herpetic neuralgia presented pain intensity similar to that of the baseline visit (median value of scores 6.6 vs. 7.0, respectively). Consistently the mean scores of anxiety, depression and quality of life were similar to those registered on acute herpes zoster presentation. On the contrary, patients without post-herpetic neuralgia presented with significantly lower levels of anxiety and depression and improved quality of life with respect to

### Table I. Demographic and Clinical Characteristics of Patients With and Without Post-Herpetic Neuralgia on Acute Herpes Zoster Presentation

<table>
<thead>
<tr>
<th></th>
<th>PHN(^a), N (%)</th>
<th>No PHN, N (%)</th>
<th>( P )</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number (%)</td>
<td>70 (32)</td>
<td>149 (68)</td>
<td>0.5920</td>
</tr>
<tr>
<td>Gender (Male/Female)</td>
<td>28 (40)/42 (60)</td>
<td>54 (36)/95 (64)</td>
<td></td>
</tr>
<tr>
<td>Age</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;50</td>
<td>13 (19)</td>
<td>57 (38)</td>
<td></td>
</tr>
<tr>
<td>50–60</td>
<td>12 (17)</td>
<td>35 (24)</td>
<td></td>
</tr>
<tr>
<td>&gt;60</td>
<td>45 (64)</td>
<td>56 (38)</td>
<td>0.0009</td>
</tr>
<tr>
<td>Years of education</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Elementary</td>
<td>25 (40)</td>
<td>42 (29)</td>
<td></td>
</tr>
<tr>
<td>Secondary</td>
<td>14 (23)</td>
<td>25 (17)</td>
<td></td>
</tr>
<tr>
<td>High school/University degree</td>
<td>23 (37)</td>
<td>79 (54)</td>
<td>0.0795</td>
</tr>
<tr>
<td>Prodromal pain</td>
<td>52 (84)</td>
<td>123 (83)</td>
<td>0.89</td>
</tr>
<tr>
<td>Duration of prodromal pain before rash (days)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>1 (2)</td>
<td>18 (15)</td>
<td></td>
</tr>
<tr>
<td>2–3</td>
<td>12 (23)</td>
<td>75 (61)</td>
<td></td>
</tr>
<tr>
<td>&gt;3</td>
<td>39 (75)</td>
<td>30 (24)</td>
<td>0.001</td>
</tr>
<tr>
<td>Intensity of pain (median value)</td>
<td>7.0</td>
<td>5.50</td>
<td>0.0155</td>
</tr>
<tr>
<td>Localization of rash</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ocular</td>
<td>13 (21)</td>
<td>14 (10)</td>
<td></td>
</tr>
<tr>
<td>Cranial</td>
<td>2 (3)</td>
<td>11 (8)</td>
<td></td>
</tr>
<tr>
<td>Cervical</td>
<td>9 (15)</td>
<td>20 (14)</td>
<td></td>
</tr>
<tr>
<td>Thoracic</td>
<td>32 (52)</td>
<td>74 (51)</td>
<td></td>
</tr>
<tr>
<td>Lumbar</td>
<td>6 (10)</td>
<td>26 (18)</td>
<td>0.11</td>
</tr>
<tr>
<td>Extent of rash (dermatomes)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>36 (58)</td>
<td>105 (73)</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>24 (39)</td>
<td>35 (24)</td>
<td></td>
</tr>
<tr>
<td>&gt;2</td>
<td>2 (3)</td>
<td>4 (3)</td>
<td>0.0354</td>
</tr>
<tr>
<td>Abnormal sensations</td>
<td>33 (47)</td>
<td>51 (34)</td>
<td>0.047</td>
</tr>
<tr>
<td>Systemic antiviral therapy</td>
<td>55 (79)</td>
<td>145 (97)</td>
<td>&lt; 0.001</td>
</tr>
</tbody>
</table>

\(^a\)Post-herpetic neuralgia.
Correlates of post-herpetic neuralgia

<table>
<thead>
<tr>
<th>TABLE II. Psychosocial Characteristics of Herpes Zoster Patients at the Baseline and at the 6-month Follow-Up Visit (Median Values of the Scores)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Acute Herpes zoster (baseline)</strong></td>
</tr>
<tr>
<td>PHN*</td>
</tr>
<tr>
<td>Anxiety</td>
</tr>
<tr>
<td>Depression</td>
</tr>
<tr>
<td>Quality of life</td>
</tr>
</tbody>
</table>

*Post-herpetic neuralgia

In the study, older age, greater pain intensity, longer duration of prodromal pain and greater extent of rash were also shown to be independent predictors of post-herpetic neuralgia by logistic regression analysis (Table III).

**DISCUSSION**

In this study older age, greater acute pain intensity, greater rash extent and longer duration of prodromal pain are independent risk factors in the development of post-herpetic neuralgia, as shown by analyzing the relationship between baseline and 6-month follow-up data in a sample of 219 Italian immunocompetent herpes zoster patients.

These and other risk factors have been examined in previous studies that have used a variety of arbitrary definitions of post-herpetic neuralgia [Hope-Simpson, 1965; Dworkin and Portenoy, 1996; Dworkin and Shmader, 2001; Jung et al., 2004].

It is known that there are three phases of pain in herpes zoster: acute herpetic neuralgia, subacute herpetic neuralgia and post-herpetic neuralgia [Arani et al., 2001; Desmond et al., 2002; Jung et al., 2004]. According to the International Herpes Management Forum, post-herpetic neuralgia is defined as the pain persisting beyond 4 months from the onset of the prodrome; the pain between 30 days from a prodrome onset and 4 months is considered subacute herpetic neuralgia; acute herpetic neuralgia is defined as the pain from the onset of herpes zoster to 30 days [Dworkin et al., 2007]. The results of research examining rates of pain resolution in clinical trials of antiviral and corticosteroid therapies in herpes zoster patients, also provide support for defining post-herpetic neuralgia as pain or dysesthesia that persists for 3 or more months after rash healing [Dworkin and Portenoy, 1994]. However, even if long-term post-herpetic neuralgia data are lacking, it is known that post-herpetic neuralgia can last for weeks, months, or even years.

In the present study, patients presenting with pain rated as “3” or more on a scale ranging from 0 (“no pain”) to 10 (“pain as bad as you can imagine”) in the last week before the follow-up visit were considered as affected by post-herpetic neuralgia. At the follow-up visit, 70 (32%) out of the 219 evaluable patients presented with post-herpetic neuralgia according the criteria adopted in this study. This percentage is higher than those previously reported [Johnson and Dworkin, 2003]. A possible bias could be represented by the fact that data from 219 out of an higher number of patients enrolled on acute herpes zoster presentation [Volpi et al., 2007] were analyzed, since not all of them returned to the physician for the 6-month follow-up visit, possibly for disease resolution. Therefore, the prevalence of post-herpetic neuralgia may be overestimated in this study.

Another potential sampling bias is that patients visiting dermatologists for diagnosis might differ from patients visiting primary care physicians. In this regard, similar studies examining herpes zoster patients on presentation to either dermatologists or general practitioners, did not report significant differences between the two groups [Di Luzio Paparatti et al., 1999; Chidiac et al., 2001; Volpi et al., 2007].

The dilemma regarding both post-herpetic neuralgia definition and comparisons regarding different reports about post-herpetic neuralgia has been illustrated by the recent Shingles UK study of post-herpetic neuralgia prevalence at 26 weeks among patients attending general practices. Using the Zoster Brief Pain

| TABLE III. Logistic Regression Model: Risk of Post-Herpetic Neuralgia |
|-------------------|-----------------|-----------------|-----------------|-----------------|
| **Effect** | **Odds Ratio Estimate** | **95% Wald Confidence Limits** | **P > χ²** |
| Class of age (years): <50 vs. >50 | 0.388 | 0.201 | 0.751 | 0.0049 |
| Antiviral therapy: yes vs. no | 0.508 | 0.103 | 2.504 | 0.4056 |
| Duration of prodromal pain (days): <3 vs. >3 | 0.487 | 0.239 | 0.991 | 0.0473 |
| Extent of rash: ≤1 vs. >1 dermatome | 0.438 | 0.223 | 0.858 | 0.0162 |
| Intensity of pain | 1.170 | 1.024 | 1.337 | 0.0210 |
| Abnormal sensations | 1.106 | 1.024 | 1.337 | 0.1635 |
Inventory, a herpes zoster specific questionnaire to quantify zoster pain and discomfort where “10” = worst imaginable pain, prevalence of post-herpetic neuralgia ranged from 3% when only pain greater than “3” was included to 17% when including any pain plus abnormal sensations [Scott et al., 2006]. In one German study, the proportion of herpes zoster patients still experiencing pain 4–5 weeks after rash crusting was reported as 28.4% [Wutzler et al., 1997]. In a retrospective study in the UK, 15% still had pain 3 months after rash appearance [Bowsher, 1999]. In a meta-analysis, 25% of placebo-treated patients with herpes zoster reported pain at 6 months [Wood et al., 1996]. At 1 year, approximately 5–10% of patients still had pain, and spontaneous resolution after post-herpetic neuralgia of this duration is limited [Bowsher, 1999]. Other surveys reported a lower incidence of post-herpetic neuralgia compared with any other published data [Helgason et al., 2000]. Not all studies have included data on pain severity, thereby increasing the difficulty of comparing respective results.

Contrary to some studies [Hope-Simpson, 1975; Meister et al., 1998; Jung et al., 2004] the results reported in this study did not establish female sex as a predictor of post-herpetic neuralgia. Similarly, Dworkin and Shmader [2001] did not find sex differences to be associated with the various aspects of herpes zoster, with the only exception being the intensity of acute pain which is higher in the female gender than in males, as also confirmed by us in a previous study [Volpi et al., 2007]. In the latter study, whereas the univariate analysis suggested that female gender was associated with more severe acute herpes zoster pain, it was shown that in multivariate analysis gender difference was obscured by depression, which was found to be more severe and more frequent in women compared to men [Volpi et al., 2007]. It is also conceivable that the earlier reported association between gender and long-term pain may have been a consequence of the fact that more women were in the higher age strata [Johnson et al., 2003]. Consistently, in the present study we found that among patients with post-herpetic neuralgia there were more females than males, similarly to what happened in patients without post-herpetic neuralgia, but also more people over 60 years of age than in the group of patients without post-herpetic neuralgia.

In the present study, the ophthalmic localization was found to be more frequent in patients presenting with post-herpetic neuralgia than in those without post-herpetic neuralgia [21% vs. 10%, respectively; P = 0.03; RR 1.77 (95% CI 1.12–2.8)], although the present study is unable to assess ophthalmic herpes zoster localization as a predictor of post-herpetic neuralgia, as previously reported by other authors [Hope-Simpson, 1975; Ragozzino et al., 1982; Decroix et al., 2000; Opstelten et al., 2002].

The presence of a prodrome, another potential predictor of post-herpetic neuralgia [Choo et al., 1997; Whitley et al., 1998; Jung et al., 2004], was not found to be associated with post-herpetic neuralgia in the patients examined in this study; however, a longer duration of prodromal pain was significantly associated with post-herpetic neuralgia (Tables I and III). On this point the data available in literature are contrasting. Opstelten et al. [2007] have reported recently that presence and duration of prodromal pain are not predictors of post-herpetic neuralgia. In contrast, multivariate analyses of large-scale studies show that the presence of a prodrome increases the risk of subsequently developing more severe acute zoster pain [Dworkin et al., 2001] and post-herpetic neuralgia [Jung et al., 2004]. There is evidence suggesting that prodromal pain could reflect subclinical Varicella zoster virus reactivation and replication in neural tissue [Garry et al., 2005], but clinical studies evaluating the suitability of Varicella zoster virus as a marker for zoster prodrome found no relationship between viral reactivation and prodromal pain [McKendrick et al., 1999]. The relationship between prodromal pain, Varicella zoster virus and post-herpetic neuralgia is probably more complex than expected and further research is needed to elucidate its nature.

The presence of abnormal sensations (dysesthesia) and the use of systemic antiviral therapy resulted to be significantly associated with post-herpetic neuralgia only in the univariate analysis. It has been shown that abnormal sensations, especially allodynia (pain evoked by the application of a mild, normally non-noxious stimulus), which is common in the first week of rash onset but subsides quickly thereafter in most patients, predicts a higher likelihood of developing post-herpetic neuralgia [Haanpaa et al., 2000]. However, the association was not sufficiently strong to predict post-herpetic neuralgia at an individual level, but the absence of allodynia at presentation was an indicator of good recovery at 3 months. Consistently, in the present study the presence of abnormal sensation was not confirmed as an independent predictor of post-herpetic neuralgia by logistic regression analysis (Table III).

Regarding the use of systemic antiviral treatment, it is generally accepted that antiviral drugs are useful but, unfortunately, they have only a limited effect on post-herpetic neuralgia prevention [Dworkin, 2006]. It has been shown very recently that the prescription of antivirals did not independently predict post-herpetic neuralgia risk [Opstelten et al., 2007], thus clear and accurate statements of their effects are needed.

Finally, it has been reported that psychological processes may contribute to post-herpetic neuralgia development [Dworkin and Banks, 1999; Livengood, 2000]. In a small prospective study, Dworkin et al. [1992] focused their attention on psychosocial post-herpetic neuralgia determinants and demonstrated that greater anxiety, greater depression, lower life satisfaction, and greater disease conviction at baseline predicted chronic zoster pain. It has been reported that the severity of the disease at presentation and depression, are the major correlates of pain burden in patients with acute herpes zoster [Katz et al., 2004; Volpi et al., 2007]. However, on the basis of the 6-month follow-up data
Correlates of Post-Herpetic Neuralgia


ACKNOWLEDGMENTS
We gratefully acknowledge the contributions of the many dermatologists who participated in this study. We are particularly indebted to Alison Inglis for her linguistic revision of the manuscript.

REFERENCES


